347 related articles for article (PubMed ID: 32816734)
1.
Isler B; Kidd TJ; Stewart AG; Harris P; Paterson DL
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816734
[No Abstract] [Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
5. New antimicrobial treatment options for severe Gram-negative infections.
Hetzler L; Kollef MH; Yuenger V; Micek ST; Betthauser KD
Curr Opin Crit Care; 2022 Oct; 28(5):522-533. PubMed ID: 35942725
[TBL] [Abstract][Full Text] [Related]
6.
Takemura M; Nakamura R; Ota M; Nakai R; Sahm DF; Hackel MA; Yamano Y
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0034623. PubMed ID: 37971240
[No Abstract] [Full Text] [Related]
7. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
8. The occurrence of Salmonella, extended-spectrum β-lactamase producing Escherichia coli and carbapenem resistant non-fermenting Gram-negative bacteria in a backyard poultry flock environment.
Shah DH; Board MM; Crespo R; Guard J; Paul NC; Faux C
Zoonoses Public Health; 2020 Sep; 67(6):742-753. PubMed ID: 32710700
[TBL] [Abstract][Full Text] [Related]
9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and
Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
[TBL] [Abstract][Full Text] [Related]
11. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
McGowan JE
Am J Med; 2006 Jun; 119(6 Suppl 1):S29-36; discussion S62-70. PubMed ID: 16735148
[TBL] [Abstract][Full Text] [Related]
12. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Hsueh PR; Chen WH; Luh KT
Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action of cefiderocol.
Soriano A; Mensa J
Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):16-19. PubMed ID: 36193980
[TBL] [Abstract][Full Text] [Related]
14. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.
Gainey AB; Burch AK; Brownstein MJ; Brown DE; Fackler J; Horne B; Biswas B; Bivens BN; Malagon F; Daniels R
Pediatr Pulmonol; 2020 Nov; 55(11):2990-2994. PubMed ID: 32662948
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Ong'uti S; Czech M; Robilotti E; Holubar M
Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis.
Tunney MM; Elborn JS; McLaughlin CS; Longshaw CM
J Glob Antimicrob Resist; 2024 Mar; 36():407-410. PubMed ID: 38336228
[TBL] [Abstract][Full Text] [Related]
17. The role of cefiderocol in clinical practice.
Maseda E; Suárez de la Rica A
Rev Esp Quimioter; 2022 Sep; 35 Suppl 2(Suppl 2):39-44. PubMed ID: 36193984
[TBL] [Abstract][Full Text] [Related]
18.
Shortridge D; Streit JM; Mendes R; Castanheira M
Microbiol Spectr; 2022 Apr; 10(2):e0271221. PubMed ID: 35262394
[TBL] [Abstract][Full Text] [Related]
19. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
Poulakou G; Giamarellou H
Expert Opin Investig Drugs; 2008 May; 17(5):749-71. PubMed ID: 18447600
[TBL] [Abstract][Full Text] [Related]
20. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
